PDCD1 and neoplasm: By interrupting the binding between receptors and tumor-derived ligands, such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell-death protein-1 (PD-1) and programmed death-ligand-1 (PD-L1), these mAbs have revolutionized the treatment of several malignancies.